Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name H19
   Synonyms H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2
   Region GRCh38_11:1995176-2001470    Sequence
   Ensembl ENSG00000130600
   RefSeq NR_002196
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name breast cancer
   ICD-0-3 C50  
   Methods qPCR, RNAi, Flow cytometry assay, Cell proliferation assay etc.
   Sample cell lines (U87 and U252)
   Expression Pattern up-regulated
   Function Description

We showed that overexpression of H19/miR-675 enhanced the aggressive phenotype of breast cancer cells including increased cell proliferation and migration in vitro, and increased tumor growth and metastasis in vivo. Moreover, we identified ubiquitin ligase E3 family (c-Cbl and Cbl-b) as direct targets of miR-675 in breast cancer cells. Using a luciferase assay, we demonstrated that H19, through its microRNA, decreased both c-Cbl and Cbl-b expression in all breast cancer cell lines tested.

   Pubmed ID 26353930
   Year 2015
   Title H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.
   External Links
   Links for  H19 GenBank       HGNC       lncrnadb       Noncode
   Links for  breast cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.